ストックスクリーナーアプリを入手
2.19
0.45%
-0.01
アフターアワーズ：
2.19
前日終値:
$2.20
開ける：
$2.2099
24時間の取引高:
8,120
Relative Volume:
0.32
時価総額：
$201.87M
収益：
$47.04M
当期純損益:
$-63.98M
株価収益率:
-2.7158
EPS:
-0.8064
ネットキャッシュフロー:
$-34.39M
1週間 パフォーマンス:
+1.39%
1か月 パフォーマンス:
-0.45%
6か月 パフォーマンス:
+42.21%
1年 パフォーマンス:
-20.36%
1日の値動き範囲:
$2.0616
$2.2099
1週間の範囲:
$2.0616
$2.2399
52週間の値動き範囲:
$1.29
$3.5107
Innate Pharma Adr Stock (IPHA) Company Profile
IPHA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
2.19 | 199.06M | 47.04M | -63.98M | -34.39M | -0.8064 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-09-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | 開始されました | Goldman | Neutral |
Innate Pharma Adr (IPHA) 最新ニュース
Earnings call transcript: Innate Pharma Q1 2025 earnings reveal strategic focus By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q1 2025 earnings reveal strategic focus - Investing.com India
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook By Investing.com - Investing.com South Africa
Innate Pharma reports promising preclinical results for cancer drug IPH4502 By Investing.com - Investing.com India
Innate Pharma stock surges on promising preclinical data By Investing.com - Investing.com South Africa
Innate Pharma reports promising preclinical results for cancer drug IPH4502 - Investing.com
H.C. Wainwright maintains $11 target on Innate Pharma stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $11 target on Innate Pharma stock - Investing.com
H.C. Wainwright maintains Buy rating on Innate Pharma stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on Innate Pharma stock - Investing.com India
Innate Pharma Reports 2024 Financial Results and Clinical Progress - TipRanks
Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances - Investing.com
Innate Pharma shares retain Buy rating on long-term strategy - Investing.com
AZN Stock Price and Chart — LSE:AZN - TradingView
Nebius Group N.V (NASDAQ: NBIS)’s Upward Trend Continues - Stocks Register
Earnings call: Innate Pharma focuses on advancing cancer therapies - Investing.com
Contrast Security Introduces Application Detection and Response (ADR) to Identify and Block Attacks and Zero Days on Applications in Production - Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
symbol__ Stock Quote Price and Forecast - CNN
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study - Zacks Investment Research
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 - Business Wire
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities.com
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
IPHA stock surges on upcoming presentation for AstraZeneca-partnered asset - Seeking Alpha
Innate Pharma Adr (IPHA) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):